Lawrence Rice, M.D.
|B.S.||University of Florida, Gainesville, FL (Zoology)|
|M.D.||Emory University School of Medicine, Atlanta, GA|
Resident, Baylor College of Medicine, Houston, TX (Internal Medicine)
Research Fellow, Baylor College of Medicine, Houston, TX (Hematology/Immunology)
Clinical Fellow, Baylor College of Medicine, Houston, TX (Hematology)
After completing an Internal Medicine Internship, Residency, and Hematology fellowship at Baylor College of Medicine, Dr. Rice was appointed to the faculty and became a Professor of Medicine and Professor of Thrombosis Research. For more than 20 years, he served as the Hematology Program Director and Director of the required medical student Hematology/Oncology course.
In 2007, his primary affiliation changed to Chief of Hematology at The Methodist Hospital and Professor of Medicine at Weill Cornell Medical College. He has maintained an active Consultative Hematology practice at Methodist for more than 30 years. This program is distinguished by the depth and breadth of the blood disorders managed, including Congenital TTP, paroxysmal nocturnal hemoglobinuria and Evans' syndrome. Two-thirds of his patients have "benign" hematologic disorders and one-third have hematologic malignancies.
Dr. Rice actively teaches medical students, residents and subspecialty fellows, and has received numerous teaching awards, including induction in the inaugural class of the Baylor Medicine Educator Hall of Fame. In 2009-2010, he received the Edward C. Lynch Outstanding Teacher Award from The Methodist Internal Medicine residents, the Methodist GME Teacher of the Year Award, the Hematology Honorary Fellow (Outstanding Teacher) Award from graduating MD Anderson Hematology/Oncology fellows, and the Hematology Educator of the Year from Baylor Hematology/Oncology fellows. Dr. Rice frequently gives lectures and chairs national educational symposia and CME events.
Dr. Rice's research interests include:
Recent clinical studies include participation in pivotal trials of novel platelet-stimulating hormones, anticoagulants, and iron-chelators.
Hematology, anemias, thrombocytopenias, anticoagulants, erythropoietin
Frame J, Rice L, Bartholomew JR, Whelton A. Rationale and Design of the PREVENT-HIT Study: A Randomized, Open-Label, Pilot Study to Compare Desirudin and Argatroban in Patients With Suspected Heparin-Induced Thrombocytopenia With or Without Thrombosis. Clinical Therapeutics. 2010;32:626-636.
Tanaka MF, Rice L. Romiplostim: therapeutic value in chronic immune thrombocytopenic purpura. Clinical Medicine Insights: Therapeutics. 2010;2:499-511.
Boyce SW, Bandyk DF, Bartholomew JR, Frame J, Rice L. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: the Prevent-HIT study. Am J Ther. 2010 Nov 11.
Cuker A, Arepally G, Crowther MA, Rice L, Datko F, Hook K, Propert KJ, Kuter DJ, Ortel TL, Konkle BA, Cines DB. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Hemost. 2010;12:2642-50.
George JN, Mathias S, Cuevas FJ, Go RS, Henry DH, Lyons R, Redner RL, Rice L, Schipperus MR. Health-related quality of life improvements for patients with chronic immune thrombocytopenic purpura receiving romiplostim: results from two randomized, placebo controlled trials. Brit J Haematol. 2009;144:409-15.
Lee P, Rice L, McCarthy JJ, Beutler E. Severe iron overload associated with a novel aminolevulinate synthase mutation and hepatitis C. Blood Cell Mol Dis. 2009;42:1-4.
Rice L. Treatment of immune thrombocytopenic purpura: focus on eltrombopag. Biologics: Targets & Therapy. 2009; 3:151-157.
Chang CC, Chen Y, Modi K, Awar OG, Alfrey CP, Rice L. Changes of red blood cell surface markers in a blood-doping model of neocytolysis. J Investig Med. 2009;57:650-4.
Bose P, Hussein KK, Terrell DR, Berger D, Rice L, George JN. Successful treatment of cyclic thrombocytopenia with thrombopoietin-mimetic agents: A report of two patients. Am J Hematol. 2009;84:459-461.
Crespo CM, Oliveira GBF, Honeycutt EF, Becker RC, Berger PB, Moliterno DJ, Anstrom KJ, Abrams CS, Kleiman NS, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Granger CB, Ohman M. Evaluation and management of suspected heparin-induced thrombocytopenia in hospitalized patients. Am Heart J. 2009;157:651-7.
Ahmed A, Powers MP, Youker KA, Dunphy CH, Ewton A, Rice L, Zu Y, Chang CC. Mast cell burden and reticulin fibrosis in the myeloproliferative neoplasms: a computer-assisted image analysis study. Pathol Research Pract. 2009;205:634-8.
Oliveira GBF, Crespo CM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, Moliterno DJ, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Ohman EM, Granger CB, for the complications after thrombocytopenia caused by heparin (CATCH) registry. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Int Med. 2008;108:94-102.
Rice L, Hursting MJ. Argatroban therapy for heparin-induced thrombocytopenia. Expert Rev in Clin Pharmacol. 2008;1:357-367.
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Sunkara UK, Liebman HA, Murali MS, Slovick FT, Vellenga E, Arepally GM, Bourgeois E, Guthrie TH, Newland A, Wasser JS, Firstenberg BA, Hamburg SI, Lahuerta-Palacios JJ, Lefrere F, Lichtin AE, Macik BG, Tanrantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo M, Nichol J. Randomized, controlled, six-month evaluation of AMG-531 in patients with chronic immune thrombocytopenic purpura. Lancet. 2008;371:395-403.
Jauregui M, Sanchez S, Ewton A, Rice L, Dunphy C, Chang CC. The role of beta-catenin in chronic myeloproliferative disorders. Human Pathol. 2008;39:1454-8.
Shahjahan M, Dunphy CH, Ewton A, Zu Y, Monzon F, Rice L, Chang CC. p38 mitogen activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes. Am J Clin Pathol. 2008;130:635-41.
Olson RJ, Dunphy CH, O'Malley DP, Rice L, Ewton AA, Chang CC. The implication of identifying JAK2V617F in myeloproliferative neoplasms and myelodysplastic syndromes with marrow fibrosis. J Hematopath. 2008;1;111-7.
Wen J, Cheng H, Rice L, Liu S, Mo A, Huang J, Zu Y, Ballon DJ, Chang CC. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Brit J Haematol. 2008; 140:169-180.
Saleem S, Rice L. Limb amputation in a patient with hemoglobin SC disease after application of ice and elevation. Am J Hematol. 2007;82:53-4.
Powers MP, Nishino H, Luo Y, Raza A, Vanguri A, Rice L, Ewton A, Zhu WL, Chang CC. Polymorphisms in TGF-beta and TNF-alpha are associated with the myelodysplastic phenotype. Arch Pathol Lab Med. 2007;131(12):1789-93.